The Connecticut Senate has passed a bill to expand a pilot program that’s meant to explore the therapeutic potential of psychedelics such as psilocybin and MDMA.
The legislation sponsored by the Joint Committee on Public Health cleared the full Senate in a unanimous 35-0 vote on Wednesday. It now heads to the House of Representatives.
If enacted into law, the proposal would build upon an existing psychedelic-assisted therapy program involving military veterans and first responders who elect to participate in clinical trials.
The new legislation would repeal and replace the current statute to make it so any adults 18 or older who meet clinical eligibility criteria established by the institutional review board of the medical school selected to administer the pilot program could be eligible to receive psychedelics treatment in a clinical setting, with researchers tasked with studying the efficacy of the novel therapeutics.
It would also remove existing language stipulating that the pilot program must end upon federal approval of psilocybin or MDMA by the Drug Enforcement Administration (DEA) or a successor agency.
Additionally, the bill would strike dated language requiring the state Department of Mental Health and Addiction Services to create and facilitate the program by January 2023.
Read full article on Marijuana Moment
